Bedford, Mass. — Rejoni, Inc. has closed a $25 million financing to support development, manufacturing and commercial preparations for its Juveena Hydrogel System.
Rejoni is a privately held clinical-stage company focused on uterine health through biomaterial therapies. The financing included new and existing investors Clavyst Bio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta Group.
The company said proceeds from the financing will be used to build the foundation for Juveena, its first product. Juveena is designed to support endometrial healing within the uterine cavity after endometrial trauma associated with intrauterine surgery, a leading cause of intrauterine adhesions.
Rejoni said it expects to scale manufacturing and supply operations, invest in market access, physician and patient engagement, and prepare for a commercial launch of Juveena if approved by the U.S. Food and Drug Administration.
“Uterine health has been underserved for too long, and this financing puts us in a position to change that. We are building the infrastructure, commercial readiness, market access, and physician engagement to ensure we can move quickly when Juveena is approved,” said John Nealon, Chief Executive Officer of Rejoni, Inc.
“This financing marks an important milestone in Rejoni’s evolution from building the science to preparing for launch. John and the team have the experience and drive to execute on this opportunity, and I remain fully committed to this mission,” said Amar Sawhney, Founder and Chairman of Rejoni, Inc.
